These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31985497)

  • 1. Lorlatinib-Associated Acute Respiratory Distress Syndrome.
    Sharma S; Kommineni K; Mehta SS; Singh H
    Am J Ther; 2020; 27(6):e698-e699. PubMed ID: 31985497
    [No Abstract]   [Full Text] [Related]  

  • 2. Podcast on the Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Bertino EM
    Adv Ther; 2022 Apr; 39(4):1447-1456. PubMed ID: 35147918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lorlatinib in ROS1-positive NSCLC.
    Killock D
    Nat Rev Clin Oncol; 2020 Jan; 17(1):7. PubMed ID: 31705129
    [No Abstract]   [Full Text] [Related]  

  • 4. Lorlatinib Exposed: A Far From Optimal Dose.
    Strohbehn GW; Ratain MJ
    Clin Pharmacol Ther; 2022 Jun; 111(6):1195-1196. PubMed ID: 35394660
    [No Abstract]   [Full Text] [Related]  

  • 5. In Response to Continuation of Lorlatinib Beyond Progressive Disease.
    Ignatius Ou SH
    J Thorac Oncol; 2022 Sep; 17(9):e86-e88. PubMed ID: 36031299
    [No Abstract]   [Full Text] [Related]  

  • 6. A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy.
    McGee K; Stone NJ; Wadhwani S; Kanwar YS; Villaflor V; Akhter N
    J Oncol Pharm Pract; 2021 Dec; 27(8):2010-2013. PubMed ID: 33789526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered.
    Zhao B; Ma W
    J Thorac Oncol; 2022 Sep; 17(9):e85-e86. PubMed ID: 36031298
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to "Lorlatinib Exposed: A Far from Optimal Dose".
    Chen J; Ruiz-Garcia A; James LP; Peltz G; Thurm H; Clancy J; Hibma J
    Clin Pharmacol Ther; 2022 Jun; 111(6):1197-1198. PubMed ID: 35358326
    [No Abstract]   [Full Text] [Related]  

  • 9. CROWN 2022 Second Interim Updates: When Will Be the Coronation of Lorlatinib?
    Nagasaka M; Ou SI
    J Thorac Oncol; 2023 Feb; 18(2):139-142. PubMed ID: 36460598
    [No Abstract]   [Full Text] [Related]  

  • 10. Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing.
    Pokorna P; Lakka Klement G; Vasikova A; Kanderova V; Jezova M; Noskova K; Mudry P; Kyr M; Merta T; Bajciova V; Krenova Z; Palova H; Valik D; Zdrazilova Dubska L; Slaby O; Sterba J
    JCO Precis Oncol; 2022 Jun; 6():e2100525. PubMed ID: 35700412
    [No Abstract]   [Full Text] [Related]  

  • 11. Neurocognitive Adverse Events of Lorlatinib: On the Way to Precise Prediction?
    Jia K; Ren S
    J Thorac Oncol; 2023 Jan; 18(1):26-28. PubMed ID: 36543433
    [No Abstract]   [Full Text] [Related]  

  • 12. Lorlatinib: a new treatment option for ROS1-positive lung cancer.
    Duruisseaux M
    Lancet Oncol; 2019 Dec; 20(12):1622-1623. PubMed ID: 31669156
    [No Abstract]   [Full Text] [Related]  

  • 13. Lorlatinib: a new-generation drug for ALK-positive NSCLC.
    Waqar SN; Morgensztern D
    Lancet Oncol; 2018 Dec; 19(12):1555-1557. PubMed ID: 30413381
    [No Abstract]   [Full Text] [Related]  

  • 14. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lorlatinib: a promising drug in the future treatment of advanced ALK-positive non-small-cell lung cancer].
    Richter J; Dunst J
    Strahlenther Onkol; 2021 Jul; 197(7):657-660. PubMed ID: 34110434
    [No Abstract]   [Full Text] [Related]  

  • 16. Lorlatinib Outperforms Crizotinib in NSCLC.
    Cancer Discov; 2021 Jan; 11(1):OF5. PubMed ID: 33298467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent.
    Desai A; Sriwastava S; Gadgeel SM; Lisak RP
    J Neurol Sci; 2018 Sep; 392():100-101. PubMed ID: 30031992
    [No Abstract]   [Full Text] [Related]  

  • 18. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
    Naito T; Shiraishi H; Fujiwara Y
    Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Stinchcombe TE
    Ann Oncol; 2021 May; 32(5):587-589. PubMed ID: 33741444
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.